How cancer and immune cell metabolism shape blood cancers and treatment response
Official title: Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Run by University Hospital, Basel, Switzerland · NCT07189117 · Data updated 2026-11-12
This project sees if the metabolism of cancer and immune cells in the bone marrow affects treatment outcomes for adults with blood cancers such as AML, MDS, ALL, and myelofibrosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 350 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | October 29, 2025 |
| Main results expected | December 2035 |
| Study ends | December 2040 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT07189117 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) who can give informed consent and have a diagnosis of AML, MDS, ALL, primary myelofibrosis, or post‑ET/PV myelofibrosis are the intended participants.
✕Probably not a fit
Pregnant or lactating people, those unable to consent, patients with other active malignancies within the past three years, and healthy donors should not expect direct therapeutic benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will perform detailed metabolic profiling of malignant cells, immune cells, and extracellular metabolites from bone marrow samples across disease stages and treatment time points. Participants include adults with hematologic malignancies (AML, MDS, ALL, primary or post‑ET/PV myelofibrosis) and healthy donors, with samples analyzed for cellular respiration, metabolite levels, and immune cell function. The goal is to map metabolic interactions that may drive therapy resistance and relapse, particularly in the context of allogeneic hematopoietic stem cell transplantation. Findings could point to metabolic pathways that are actionable targets for new treatments or for tailoring existing therapies to individual patients.
Why it matters
Potential benefit: If successful, the work could reveal metabolic targets or biomarkers that help reduce relapse and guide more personalized treatment strategies for patients with blood cancers.
How similar studies have gone: Preclinical and early clinical work suggests metabolic pathways can influence cancer and immune responses, but comprehensive human bone marrow metabolic profiling in these blood cancers remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years, * signed written informed consent * For participants with hematological cancers: diagnosis of MDS, AML, ALL, PMF or post-ET/PV MF Exclusion Criteria: * pregnant or lactating women, * inability to give consent, * active malignant disease (other than MDS, AML, ALL, PMF or post-ET/PV MF in the last 3 - years prior to study inclusion). * For healthy donors: previous or current hematological disease, previous or current other malignant disease,
Where it's running
-
University Hospital Basel
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Johannes Tossounidis, MD — University Hospital of Basel
- Study coordinator: Petya Apostolova, Prof. Dr.
- Email: petya.apostolova@unibas.ch
- Phone: +41 61 328 48 40
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy
This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.
-
CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant
This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.
-
Identifying biomarkers for CAR-T cell therapy in cancer patients
This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.
-
QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors
This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.
-
Short versus long maribavir treatment after allogeneic stem cell transplant
This trial tests whether a shorter or longer course of maribavir helps adults with refractory CMV infection after their first allogeneic stem cell transplant.
-
Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients
This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.